Alfredo Berruti
ASST Spedali Civili di Brescia and University of Brescia · Asst Degli Spedali Civili Di Brescia · Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Alfredo Berruti as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 01:02 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT07085572 · Cemiplimab as Maintenance Treatment for Advanced Adrenocortical CancerAzienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia · recruiting · Adrenal Cortical Carcinoma · principal investigator
- Ph2NCT05913427 · Evaluation of the Efficacy of Addition of Progesterone to Standard Chemotherapy in Adrenocortical Carcinoma (ACC)Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia · recruiting · Adrenocortical Carcinoma · principal investigator
- Ph2NCT05265988 · Multiparametric Assessment of Bone Response in mCRPC Patients Treated With CabozantinibAlfredo Berruti · completed · Carcinoma Prostate · principal investigator
- Ph3NCT03723941 · Adjuvant Chemotherapy vs. Observation/Mitotane After Primary Surgical Resection of Localized Adrenocortical CarcInomaAzienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia · completed · Adrenocortical Carcinoma · principal investigator
- Ph2NCT03336983 · Luteinizing Hormone-releasing Hormone Analogue and Enzalutamide +/- Zoledronic Acid in Prostate Cancer PatientsAzienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia · completed · Prostate Cancer, Bone Metastases · principal investigator
- Ph2NCT03257891 · Cabazitaxel Activity in Patients With Advanced AdrenoCortical-Carcinoma Progressing After Previous Chemotherapy LinesAzienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia · unknown · Adrenocortical Carcinoma · principal investigator
- Ph3NCT01224405 · Prostate Cancer, Androgen Deprivation Withdrawal and Intermittent ChemotherapyUniversity of Turin, Italy · unknown · Advanced Prostate Cancer · study chair
- Ph2NCT01203306 · Bevacizumab Plus Somatostatin Analogue and Metronomic Capecitabine in Patients With Advanced Neuroendocrine TumorsUniversity of Turin, Italy · unknown · Neuroendocrine Carcinomas · study director
- Ph2NCT00954135 · Letrozole Plus Oral Cyclophosphamide Plus/Minus Sorafenib as Primary Systemic Treatment in Breast Cancer PatientsUniversity of Turin, Italy · unknown · Breast Cancer · study chair
- Ph2NCT00953394 · 5FU and Octreotide Long-acting Release (LAR) for Neuroendocrine TumorsUniversity of Turin, Italy · completed · Neuroendocrine Tumors · study chair
- Ph2NCT00786110 · Sorafenib Plus Paclitaxel in Adreno-Cortical-Cancer PatientsUniversity of Turin, Italy · unknown · Adrenocortical Carcinoma · study chair
- Ph3NCT00777244 · Efficacy of Adjuvant Mitotane Treatment (ADIUVO)University of Turin, Italy · unknown · Adrenocortical Carcinoma · study chair
Grants
NIH projects from RePORTER, fetched 2026-11-12 01:02 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 01:02 UTC. The ranking covers the 200 most relevant of 75 PubMed records, and a shared surname and initials can bring in a namesake. All 75 on PubMed
- Combination chemotherapy in advanced adrenocortical carcinoma.N Engl J Med · 2012674 citationsRCR 19.4
- Linsitinib (OSI-906) versus placebo for patients with locally advanced or metastatic adrenocortical carcinoma: a double-blind, randomised, phase 3 study.Lancet Oncol · 2015281 citationsRCR 8.6
- Etoposide, doxorubicin and cisplatin plus mitotane in the treatment of advanced adrenocortical carcinoma: a large prospective phase II trial.Endocr Relat Cancer · 2005231 citationsRCR 5.8
- Hypoxia-inducible factor-1alpha expression predicts a poor response to primary chemoendocrine therapy and disease-free survival in primary human breast cancer.Clin Cancer Res · 2006219 citationsRCR 4.5
- Randomized phase II trial of letrozole and letrozole plus low-dose metronomic oral cyclophosphamide as primary systemic treatment in elderly breast cancer patients.J Clin Oncol · 2006153 citationsRCR 3.1
- Gemcitabine plus metronomic 5-fluorouracil or capecitabine as a second-/third-line chemotherapy in advanced adrenocortical carcinoma: a multicenter phase II study.Endocr Relat Cancer · 2010114 citationsRCR 3.1
- Phase II study of weekly paclitaxel and sorafenib as second/third-line therapy in patients with adrenocortical carcinoma.Eur J Endocrinol · 2012112 citationsRCR 3.3
- 109 citationsRCR 4.3
- Lenvatinib in Patients With Advanced Grade 1/2 Pancreatic and Gastrointestinal Neuroendocrine Tumors: Results of the Phase II TALENT Trial (GETNE1509).J Clin Oncol · 2021106 citationsRCR 7.0
- 106 citationsRCR 2.7